December 9th 2024
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.
October 2nd 2024
The best strategy is to use a combination of complementary methods.
July 3rd 2024
A greater number of patients with Duchenne muscular dystrophy will be able to be treated after FDA's approval of a gene therapy.
May 30th 2024
A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
May 25th 2024
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.